Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 29Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × Automobiles × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
1 enrolled 8 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡